Oruka Therapeutics, Inc.
ORKAOruka Therapeutics, Inc. in brief
Oruka Therapeutics, Inc. is a listed company in the Biotechnology industry, based in the USA. Its market value was $6.5 B on 28 October 2026, which makes it the 2,970th largest listed company in the world and the 897th largest in the USA on this site. It employs about 68 people. Its shares trade under the symbol ORKA (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Oruka Therapeutics, Inc.
On August 29, 2024, we completed our acquisition of Oruka Therapeutics, Inc. pursuant to an Agreement and Plan of Merger and Reorganization, dated as of April 3, 2024. Following the transactions contemplated by the Merger Agreement, Pre-Merger Oruka merged with and into Atlas Merger Sub Corp., a wholly owned subsidiary of ARCA biopharma, Inc. and following that, Pre-Merger Oruka then merged with and into Atlas Merger Sub II, LLC, with Second Merger Sub being the surviving entity. Second Merger Sub changed its corporate name to “Oruka Therapeutics Operating Company, LLC”. Pre-Merger Oruka was a pre-clinical stage biotechnology company that was incorporated on February 6, 2024 under the direction of Peter Harwin, a Founding Partner at Fairmount Funds Management LLC, for the purposes of holding rights to certain intellectual property being developed by Paragon Therapeutics, Inc.. On August 29, 2024, we changed our name from “ARCA biopharma, Inc.” to “Oruka Therapeutics, Inc.” and our Nasdaq ticker symbol from “ABIO” to “ORKA”.
Oruka Therapeutics, Inc. timeline
- 1997
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2003
- ✎Renamed Nuvelo IncFormerly Hyseq Inc.
- 2009
- ✎Renamed ARCA biopharma, Inc.Formerly Nuvelo Inc.
- 2024
- ✎Renamed Oruka Therapeutics, Inc.Formerly ARCA biopharma, Inc..
Events of Oruka Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,695 (Jan 2020) · #4,194 (Jan 2021) · #5,192 (Jan 2022) · #5,023 (Dec 2022) · #5,026 (Jul 2023) · #4,310 (Jan 2024) · #898 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 13.8×
- Free cash flow yield
- -1.4%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -22.3%
- Liabilities / assets
- 3.4%
- Profit per employee
- $-1.6 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-122M | $-105M | — |
| Dec 2024 | — | — | $-88M | $-84M | — |
| Dec 2023 | — | — | $-7M | $-5M | — |
| Dec 2022 | — | — | $-11M | $-10M | — |
| Dec 2021 | — | — | $-19M | $-19M | — |
| Dec 2020 | — | — | $-10M | $-10M | — |
| Dec 2019 | — | — | $-6M | $-5M | — |
| Dec 2018 | — | — | $-8M | $-8M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-88M | $0M | $-88M | — | — |
| Dec 2024 | $-58M | $0M | $-58M | $-3.87 | — |
| Dec 2023 | $-5M | $0M | $-5M | $-0.37 | — |
| Dec 2022 | $-11M | $0M | $-11M | $-0.69 | — |
| Dec 2021 | $-19M | $0M | $-19M | $-1.39 | — |
| Dec 2020 | $-8M | $0M | $-8M | $-2.07 | — |
| Dec 2019 | $-5M | $0M | $-5M | $-4.15 | — |
| Dec 2018 | $-8M | $0M | $-8M | $-10.31 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-50M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 9, 202610-QQuarterly report · period to Sep 2026
- Oct 26, 20268-KCurrent reportRegulation FD disclosure · Other events
- Aug 24, 20268-KCurrent reportDirectors or officers changed
- Aug 10, 202610-QQuarterly report · period to Jun 2026
- Aug 10, 20268-KCurrent reportResults of operations
- Jun 4, 20268-KCurrent reportShareholder vote
- Jun 1, 20268-KCurrent reportOther events
- May 13, 202610-QQuarterly report · period to Mar 2026
- Apr 30, 20268-KCurrent reportResults of operations · Other events
- Apr 27, 20268-KCurrent reportRegulation FD disclosure · Other events
- Apr 17, 2026DEF 14AProxy statement
- Mar 12, 202610-KAnnual report · period to Dec 2025
Official filings of Oruka Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-122 M
- Net income
- $-105 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $489 M
- Total liabilities
- $17 M
- Total equity
- $472 M
As of December-2025
Top 100 institutional investors in Oruka Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 10,148,867 | +1,091,222 (+12.05%) | 14.96% | $845 M | Nov 10, 2026 |
| 2 | BlackRock, Inc. | 5,210,214 | +220,033 (+4.41%) | 7.68% | $434 M | Nov 13, 2026 |
| 3 | T. Rowe Price Investment Management, Inc. | 4,392,166 | +3,288,423 (+297.93%) | 6.48% | $366 M | Nov 16, 2026 |
| 4 | Venrock Adviser, LLC | 4,148,428 | 0 (0.00%) | 6.12% | $346 M | Nov 16, 2026 |
| 5 | Fairmount Funds Management LLC | 3,705,262 | 0 (0.00%) | 5.46% | $309 M | Nov 16, 2026 |
| 6 | Capital World Investors | 3,429,066 | +27,427 (+0.81%) | 5.06% | $286 M | Nov 12, 2026 |
| 7 | RTW Investments, LP | 3,139,030 | 0 (0.00%) | 4.63% | $261 M | Nov 16, 2026 |
| 8 | State Street Corp | 2,817,132 | +144,042 (+5.39%) | 4.15% | $235 M | Nov 12, 2026 |
| 9 | Vanguard Capital Management LLC | 2,644,280 | +283,309 (+12.00%) | 3.90% | $220 M | Nov 13, 2026 |
| 10 | Paradigm Biocapital Advisors LP | 2,493,507 | +348,981 (+16.27%) | 3.68% | $208 M | Nov 16, 2026 |
| 11 | Franklin Templeton Inc | 2,033,669 | +412,218 (+25.42%) | 3.00% | $169 M | Nov 12, 2026 |
| 12 | Janus Henderson Group Ltd. | 1,873,153 | — | 2.76% | $156 M | Nov 16, 2026 |
| 13 | Bellevue Group AG | 1,641,059 | -16,131 (-0.97%) | 2.42% | $137 M | Nov 16, 2026 |
| 14 | Vanguard Portfolio Management LLC | 1,592,427 | +1,010,018 (+173.42%) | 2.35% | $133 M | Nov 13, 2026 |
| 15 | Ra Capital Management, L.P. | 1,554,597 | 0 (0.00%) | 2.29% | $129 M | Nov 16, 2026 |
| 16 | Geode Capital Management, LLC | 1,545,458 | +115,504 (+8.08%) | 2.28% | $129 M | Nov 6, 2026 |
| 17 | Polar Capital Holdings Plc | 1,224,841 | -3,768 (-0.31%) | 1.81% | $102 M | Nov 16, 2026 |
| 18 | Perceptive Advisors LLC | 1,072,363 | -272,700 (-20.27%) | 1.58% | $89 M | Nov 16, 2026 |
| 19 | Deep Track Capital, LP | 1,069,774 | -856,226 (-44.46%) | 1.58% | $89 M | Nov 16, 2026 |
| 20 | Price T Rowe Associates Inc /MD/ | 966,767 | +128,164 (+15.28%) | 1.43% | $81 M | Nov 16, 2026 |
| 21 | Remedium Capital Partners, LLC | 954,150 | -611,511 (-39.06%) | 1.41% | $79 M | Nov 13, 2026 |
| 22 | Westfield Capital Management Co LP | 829,749 | +198,316 (+31.41%) | 1.22% | $69 M | Nov 12, 2026 |
| 23 | Avidity Partners Management LP | 785,424 | +25,000 (+3.29%) | 1.16% | $65 M | Nov 16, 2026 |
| 24 | Summit Partners Public Asset Management, LLC | 723,922 | +65,621 (+9.97%) | 1.07% | $60 M | Nov 16, 2026 |
| 25 | Jpmorgan Chase & Co | 695,630 | +40,603 (+6.20%) | 1.03% | $58 M | Nov 12, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Aberdeen Group plc | 632,408 | -14,535 (-2.25%) | 0.93% | $53 M | Nov 10, 2026 |
| 27 | Affinity Asset Advisors, LLC | 600,000 | +10,000 (+1.69%) | 0.88% | $50 M | Nov 13, 2026 |
| 28 | Goldman Sachs Group Inc | 582,289 | +402,850 (+224.51%) | 0.86% | $48 M | Nov 16, 2026 |
| 29 | Charles Schwab Investment Management Inc | 520,681 | +87,276 (+20.14%) | 0.77% | $43 M | Nov 16, 2026 |
| 30 | BNP Paribas Financial Markets | 459,528 | -619,487 (-57.41%) | 0.68% | $38 M | Nov 12, 2026 |
| 31 | Northern Trust Corp | 446,386 | +17,495 (+4.08%) | 0.66% | $37 M | Nov 16, 2026 |
| 32 | Voya Investment Management LLC | 412,814 | +11,665 (+2.91%) | 0.61% | $34 M | Nov 10, 2026 |
| 33 | Vanguard Fiduciary Trust Co | 403,555 | +37,925 (+10.37%) | 0.59% | $34 M | Nov 13, 2026 |
| 34 | Pictet Asset Management Holding SA | 401,928 | -217,148 (-35.08%) | 0.59% | $33 M | Nov 3, 2026 |
| 35 | Cormorant Asset Management, LP | 400,000 | -133,340 (-25.00%) | 0.59% | $33 M | Nov 16, 2026 |
| 36 | Adage Capital Partners GP, L.L.C. | 394,246 | +39,243 (+11.05%) | 0.58% | $33 M | Nov 16, 2026 |
| 37 | Point72 Asset Management, L.P. | 373,455 | New | 0.55% | $31 M | Nov 16, 2026 |
| 38 | Massachusetts Financial Services Co /ma/ | 345,003 | -19,099 (-5.25%) | 0.51% | $29 M | Nov 12, 2026 |
| 39 | Candriam S.C.A. | 339,032 | -13,684 (-3.88%) | 0.50% | $28 M | Nov 3, 2026 |
| 40 | UBS Group AG | 320,044 | -319,319 (-49.94%) | 0.47% | $27 M | Nov 10, 2026 |
| 41 | Braidwell LP | 319,679 | +41,515 (+14.92%) | 0.47% | $27 M | Nov 16, 2026 |
| 42 | Lord, Abbett & Co. LLC | 306,236 | -83,828 (-21.49%) | 0.45% | $26 M | Nov 13, 2026 |
| 43 | Jennison Associates LLC | 301,727 | +2,470 (+0.83%) | 0.44% | $25 M | Nov 16, 2026 |
| 44 | MPM Bioimpact LLC | 300,000 | New | 0.44% | $25 M | Nov 16, 2026 |
| 45 | Ghisallo Capital Management LLC | 300,000 | +250,000 (+500.00%) | 0.44% | $25 M | Nov 16, 2026 |
| 46 | Eventide Asset Management, LLC | 295,000 | +55,000 (+22.92%) | 0.43% | $25 M | Nov 13, 2026 |
| 47 | Holocene Advisors, LP | 291,573 | -14,378 (-4.70%) | 0.43% | $24 M | Nov 16, 2026 |
| 48 | Woodline Partners LP | 285,952 | +705 (+0.25%) | 0.42% | $24 M | Nov 16, 2026 |
| 49 | Bank Of America Corp /de/ | 281,363 | -71,461 (-20.25%) | 0.41% | $23 M | Nov 16, 2026 |
| 50 | Silverarc Capital Management, LLC | 247,918 | -104,884 (-29.73%) | 0.37% | $21 M | Nov 12, 2026 |
| 51 | Nuveen, LLC | 241,116 | -8,151 (-3.27%) | 0.36% | $20 M | Nov 10, 2026 |
| 52 | Nomura Asset Management International Inc. | 231,345 | +12,306 (+5.62%) | 0.34% | $19 M | Nov 16, 2026 |
| 53 | Blackstone Inc. | 219,709 | -17,399 (-7.34%) | 0.32% | $18 M | Nov 16, 2026 |
| 54 | Fisher Asset Management, LLC | 215,593 | +147,719 (+217.64%) | 0.32% | $18 M | Nov 6, 2026 |
| 55 | Deutsche Bank AG\ | 198,924 | +3,720 (+1.91%) | 0.29% | $17 M | Nov 6, 2026 |
| 56 | SEB Asset Management AB | 196,753 | 0 (0.00%) | 0.29% | $16 M | Nov 4, 2026 |
| 57 | Barclays PLC | 170,500 | +95,738 (+128.06%) | 0.25% | $14 M | Nov 6, 2026 |
| 58 | Handelsbanken Fonder AB | 165,077 | +4,177 (+2.60%) | 0.24% | $14 M | Nov 9, 2026 |
| 59 | Millennium Management LLC | 158,558 | +125,692 (+382.44%) | 0.23% | $13 M | Nov 16, 2026 |
| 60 | Bank of New York Mellon Corp | 143,461 | +2,591 (+1.84%) | 0.21% | $12 M | Nov 5, 2026 |
| 61 | Victory Capital Management Inc | 130,940 | +6,662 (+5.36%) | 0.19% | $11 M | Nov 10, 2026 |
| 62 | Dimensional Fund Advisors LP | 128,645 | +15,469 (+13.67%) | 0.19% | $11 M | Nov 4, 2026 |
| 63 | TD Asset Management Inc | 128,562 | +25,618 (+24.89%) | 0.19% | $11 M | Nov 13, 2026 |
| 64 | Synergy Asset Management, LLC | 127,852 | -228,449 (-64.12%) | 0.19% | $11 M | Nov 5, 2026 |
| 65 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 124,390 | +20,080 (+19.25%) | 0.18% | $10 M | Nov 16, 2026 |
| 66 | Morgan Stanley | 121,869 | +45,509 (+59.60%) | 0.18% | $10 M | Nov 13, 2026 |
| 67 | Seven Grand Managers, LLC | 110,000 | 0 (0.00%) | 0.16% | $9 M | Nov 16, 2026 |
| 68 | Russell Investments Group, Ltd. | 104,433 | -8,510 (-7.53%) | 0.15% | $9 M | Nov 6, 2026 |
| 69 | Squarepoint Ops LLC | 100,996 | New | 0.15% | $8 M | Nov 9, 2026 |
| 70 | Invesco Ltd. | 97,255 | -27,403 (-21.98%) | 0.14% | $8 M | Nov 12, 2026 |
| 71 | Apis Capital Advisors, LLC | 92,000 | -20,000 (-17.86%) | 0.14% | $8 M | Nov 13, 2026 |
| 72 | Toronto Dominion Bank | 89,837 | 0 (0.00%) | 0.13% | $7 M | Nov 16, 2026 |
| 73 | Alps Advisors Inc | 87,745 | +26,731 (+43.81%) | 0.13% | $7 M | Nov 3, 2026 |
| 74 | Schroder Investment Management Group | 81,088 | +59,635 (+277.98%) | 0.12% | $7 M | Nov 16, 2026 |
| 75 | Neuberger Berman Group LLC | 79,473 | +77,263 (+3496.06%) | 0.12% | $7 M | Nov 13, 2026 |
| 76 | Swiss National Bank | 77,400 | +14,400 (+22.86%) | 0.11% | $6 M | Nov 12, 2026 |
| 77 | Prudential Financial Inc | 76,620 | -9,275 (-10.80%) | 0.11% | $6 M | Nov 16, 2026 |
| 78 | Moody Aldrich Partners LLC | 74,806 | -26,605 (-26.23%) | 0.11% | $6 M | Oct 27, 2026 |
| 79 | Ameriprise Financial Inc | 72,088 | -646 (-0.89%) | 0.11% | $6 M | Nov 16, 2026 |
| 80 | Rafferty Asset Management, LLC | 69,824 | +26,714 (+61.97%) | 0.10% | $6 M | Nov 13, 2026 |
| 81 | Alliancebernstein L.P. | 64,580 | -1,500 (-2.27%) | 0.10% | $5 M | Nov 16, 2026 |
| 82 | Marshall Wace, LLP | 63,668 | New | 0.09% | $5 M | Nov 13, 2026 |
| 83 | First Trust Advisors LP | 62,885 | +58,222 (+1248.60%) | 0.09% | $5 M | Nov 12, 2026 |
| 84 | Secure Asset Management, LLC | 62,452 | -3,447 (-5.23%) | 0.09% | $5 M | Oct 19, 2026 |
| 85 | Rhumbline Advisers | 62,380 | +1,596 (+2.63%) | 0.09% | $5 M | Nov 10, 2026 |
| 86 | Manufacturers Life Insurance Company, The | 61,757 | -6,664 (-9.74%) | 0.09% | $5 M | Nov 13, 2026 |
| 87 | Atom Investors LP | 61,227 | +45,706 (+294.48%) | 0.09% | $5 M | Nov 16, 2026 |
| 88 | Federated Hermes, Inc. | 60,446 | +30,364 (+100.94%) | 0.09% | $5 M | Nov 12, 2026 |
| 89 | Granahan Investment Management, LLC | 59,676 | +8,638 (+16.92%) | 0.09% | $5 M | Nov 16, 2026 |
| 90 | Informed Momentum Co LLC | 59,649 | +635 (+1.08%) | 0.09% | $5 M | Nov 16, 2026 |
| 91 | Principal Financial Group Inc | 58,837 | +19,061 (+47.92%) | 0.09% | $5 M | Nov 2, 2026 |
| 92 | Ensign Peak Advisors, Inc | 58,707 | -8,961 (-13.24%) | 0.09% | $5 M | Nov 12, 2026 |
| 93 | Viking Global Investors LP | 58,000 | -1,445,478 (-96.14%) | 0.09% | $5 M | Nov 16, 2026 |
| 94 | Rhenman & Partners Asset Management AB | 55,900 | -24,100 (-30.12%) | 0.08% | $5 M | Nov 12, 2026 |
| 95 | B Group, Inc. | 55,000 | -20,000 (-26.67%) | 0.08% | $5 M | Nov 16, 2026 |
| 96 | Parkman Healthcare Partners LLC | 53,221 | -59,967 (-52.98%) | 0.08% | $4 M | Nov 16, 2026 |
| 97 | Burkehill Global Management, LP | 50,000 | 0 (0.00%) | 0.07% | $4 M | Nov 16, 2026 |
| 98 | Kennedy Capital Management LLC | 47,140 | -59,723 (-55.89%) | 0.07% | $4 M | Nov 13, 2026 |
| 99 | XTX Topco Ltd | 45,345 | +4,839 (+11.95%) | 0.07% | $4 M | Nov 16, 2026 |
| 100 | California State Teachers Retirement System | 44,120 | +8,100 (+22.49%) | 0.07% | $4 M | Nov 13, 2026 |
Superinvestors holding Oruka Therapeutics, Inc.
2 of the well-known investors value.today follows, from their newest Form 13F.
- Viking Global Investors · Andreas Halvorsen$5 M−1.4 M · Sep 30, 2026
- Polen Capital · Polen Capital's team$3 Mnew · Sep 30, 2026
Mutual funds holding Oruka Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 1.72 M | $164 M | 2.5% | <0.01% | +25% | Jun 30, 2026 |
| 🇺🇸 State Street SPDR S&P Biotech ETFSSGA Funds Management, Inc. | 1.56 M | $148 M | 2.3% | 1.4% | +104% | Jun 30, 2026 |
| 🇺🇸 SMALLCAP World Fund IncSMALLCAP World Fund Inc | 1.53 M | $145 M | 2.3% | 0.15% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 1.30 M | $124 M | 1.9% | 0.15% | +38% | Jun 30, 2026 |
| 🇺🇸 Fidelity Growth Company FundFidelity Management & Research Company LLC | 1.22 M | $71 M | 1.8% | 0.07% | +200% | May 31, 2026 |
| 🇺🇸 Fidelity Advisor Biotechnology FundFidelity Management & Research Company LLC | 737,386 | $71 M | 1.1% | 3.2% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Growth FundFidelity Management & Research Company LLC | 685,718 | $66 M | 1.0% | 0.75% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 580,953 | $55 M | 0.86% | 0.06% | +33% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 550,743 | $53 M | 0.81% | 0.16% | +44% | Jul 31, 2026 |
| 🇺🇸 Select Health Care PortfolioFidelity Management & Research Company LLC | 833,100 | $49 M | 1.2% | 0.84% | −17% | May 31, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences Fund, Inc.T. Rowe Price Associates, Inc. | 451,118 | $43 M | 0.67% | 0.36% | −5.2% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 449,195 | $43 M | 0.66% | 0.28% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Advisor Health Care FundFidelity Management & Research Company LLC | 428,000 | $41 M | 0.63% | 1.3% | +0.9% | Jul 31, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Stock Fund, Inc.T. Rowe Price Associates, Inc. | 381,128 | $36 M | 0.56% | 0.39% | new | Jun 30, 2026 |
| 🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors | 359,218 | $34 M | 0.53% | 0.38% | +18% | Jun 30, 2026 |
| 🇺🇸 Fidelity Stock Selector Small Cap FundFidelity Management & Research Company LLC | 344,956 | $33 M | 0.51% | 0.45% | no change | Jul 31, 2026 |
| 🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC | 562,683 | $33 M | 0.83% | 0.63% | +18% | May 31, 2026 |
| 🇺🇸 Harbor Small Cap Growth FundHarbor Capital Advisors, Inc. | 316,518 | $31 M | 0.47% | 1.1% | +186% | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Small Cap Opportunities FundFidelity Management & Research Company LLC | 301,472 | $29 M | 0.44% | 0.61% | no change | Jul 31, 2026 |
| 🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc. | 296,262 | $29 M | 0.44% | 2.5% | −6.4% | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Growth K6 FundFidelity Management & Research Company LLC | 295,854 | $29 M | 0.44% | 0.62% | no change | Jul 31, 2026 |
| 🇺🇸 abrdn Healthcare Investorsabrdn Inc. | 273,474 | $26 M | 0.40% | 1.9% | new | Jun 30, 2026 |
| 🇺🇸 Putnam Small Cap Growth FundPutnam Investment Management, LLC | 255,628 | $24 M | 0.38% | 0.72% | new | Jun 30, 2026 |
| 🇺🇸 JPMorgan Small Cap Growth FundJ.P. Morgan Investment Management Inc. | 250,999 | $24 M | 0.37% | 0.92% | new | Jun 30, 2026 |
| 🇺🇸 abrdn Healthcare Opportunities Fundabrdn Inc. | 250,767 | $24 M | 0.37% | 2.9% | new | Jun 30, 2026 |
| 🇺🇸 Eventide Healthcare & Life Sciences FundEventide Asset Management, LLC | 240,000 | $23 M | 0.35% | 1.3% | new | Jun 30, 2026 |
| 🇺🇸 Lord Abbett Developing Growth Fund IncLord, Abbett & Co. LLC | 225,118 | $22 M | 0.33% | 0.98% | +4.7% | Jul 31, 2026 |
| 🇺🇸 Janus Henderson Global Life Sciences FundJanus Investment Fund | 222,082 | $21 M | 0.33% | 0.36% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Growth Company K6 FundFidelity Management & Research Company LLC | 356,248 | $21 M | 0.53% | 0.08% | +192% | May 31, 2026 |
| 🇺🇸 Franklin Small Cap Growth FundFranklin Advisers, Inc. | 208,013 | $20 M | 0.31% | 0.81% | −2.4% | Jul 31, 2026 |
| 🇺🇸 T. Rowe Price Institutional Small-Cap Stock FundT. Rowe Price Associates, Inc. | 205,065 | $20 M | 0.30% | 0.39% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Growth Company FundFidelity Management & Research Company LLC | 323,236 | $19 M | 0.48% | 0.08% | +203% | May 31, 2026 |
| 🇸🇪 SEB LäkemedelsfondSEB Funds AB | 196,753 | $19 M | 0.29% | 1.0% | new | Jun 30, 2026 |
| 🇺🇸 Nomura Healthcare FundDelaware Management Company | 190,000 | $18 M | 0.28% | 2.4% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity ContrafundFidelity Management & Research Company LLC | 185,075 | $18 M | 0.27% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 New Economy FundCapital Research and Management Company | 285,714 | $17 M | 0.42% | 0.03% | new | May 31, 2026 |
| 🇺🇸 BlackRock Health Sciences Opportunities PortfolioBlackRock Advisors, LLC | 264,813 | $15 M | 0.39% | 0.26% | +43% | May 29, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 252,250 | $15 M | 0.37% | 0.03% | +24% | May 31, 2026 |
| 🇺🇸 T. Rowe Price Integrated U.S. Small-Cap Growth Equity FundT. Rowe Price Associates, Inc. | 150,800 | $14 M | 0.22% | 0.15% | new | Jun 30, 2026 |
| 🇺🇸 VIP Health Care PortfolioFidelity Management & Research Company LLC | 149,300 | $14 M | 0.22% | 1.2% | −7.9% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 237,730 | $14 M | 0.35% | 0.08% | +24% | May 31, 2026 |
| 🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc. | 234,870 | $14 M | 0.35% | 0.06% | +22% | May 31, 2026 |
| 🇺🇸 Fidelity Blue Chip Growth FundFidelity Management & Research Company LLC | 129,200 | $12 M | 0.19% | 0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 122,470 | $12 M | 0.18% | 0.16% | +45% | Jul 31, 2026 |
| 🇺🇸 abrdn Life Sciences Investorsabrdn Inc. | 122,702 | $12 M | 0.18% | 1.7% | +62% | Jun 30, 2026 |
| 🇺🇸 Fidelity SAI Small-Mid Cap Momentum Index FundFidelity Management & Research Company LLC | 119,794 | $12 M | 0.18% | 0.28% | new | Jul 31, 2026 |
| 🇸🇪 Handelsbanken Hälsovård TemaHandelsbanken Fonder AB | 107,000 | $10 M | 0.16% | 0.40% | new | Jun 30, 2026 |
| 🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC | 96,464 | $9 M | 0.14% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 92,609 | $9 M | 0.14% | 0.15% | +49% | Jun 30, 2026 |
| 🇺🇸 Janus Henderson Small/Mid Cap Growth Alpha ETFJanus Henderson Investors US LLC | 82,097 | $8 M | 0.12% | 0.75% | new | Jul 31, 2026 |
| 🇺🇸 JPMorgan Small Cap Blend FundJ.P. Morgan Investment Management Inc. | 80,748 | $8 M | 0.12% | 0.45% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Explorer FundThe Vanguard Group, Inc. | 78,586 | $8 M | 0.12% | 0.03% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity U.S. Equity Central FundFidelity Management & Research Company LLC | 75,600 | $7 M | 0.11% | 0.03% | new | Jun 30, 2026 |
| 🇺🇸 MFS New Discovery Value FundMASSACHUSETTS FINANCIAL SERVICES COMPANY | 122,006 | $7 M | 0.18% | 0.29% | new | May 31, 2026 |
| 🇺🇸 MFS New Discovery FundMASSACHUSETTS FINANCIAL SERVICES COMPANY | 121,469 | $7 M | 0.18% | 0.33% | new | May 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 74,423 | $7 M | 0.11% | 0.07% | +333% | Jun 30, 2026 |
| 🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors | 67,743 | $6 M | 0.10% | <0.01% | +20% | Jun 30, 2026 |
| 🇺🇸 Invesco Dorsey Wright Healthcare Momentum ETFInvesco Capital Management LLC | 66,716 | $6 M | 0.10% | 2.7% | +136% | Jul 31, 2026 |
| 🇺🇸 Strategic Advisers Fidelity U.S. Total Stock FundStrategic Advisers LLC | 108,900 | $6 M | 0.16% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 65,695 | $6 M | 0.10% | 0.16% | +46% | Jul 31, 2026 |
| 🇺🇸 BlackRock Health Sciences Term TrustBlackRock Advisors, LLC | 65,030 | $6 M | 0.10% | 0.57% | +34% | Jun 30, 2026 |
| 🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc. | 94,188 | $6 M | 0.14% | 0.03% | +44% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 92,125 | $5 M | 0.14% | <0.01% | +22% | May 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 54,205 | $5 M | 0.08% | 0.14% | +36% | Jun 30, 2026 |
| 🇺🇸 Direxion Daily S&P Biotech Bull 3X SharesRAFFERTY ASSET MANAGEMENT, LLC | 52,700 | $5 M | 0.08% | 1.0% | +21% | Jul 31, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 81,774 | $5 M | 0.12% | 0.17% | +39% | May 31, 2026 |
| 🇺🇸 Victory RS Small Cap Growth FundVictory Capital Management Inc. | 48,680 | $5 M | 0.07% | 1.1% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 47,198 | $4 M | 0.07% | 0.29% | new | Jun 30, 2026 |
| 🇺🇸 VIP Contrafund PortfolioFidelity Management & Research Company LLC | 47,000 | $4 M | 0.07% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 PGIM Jennison Health Sciences FundPGIM INVESTMENTS LLC | 76,396 | $4 M | 0.11% | 0.32% | new | May 29, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 75,066 | $4 M | 0.11% | <0.01% | +21% | May 31, 2026 |
| 🇺🇸 VictoryShares US Small Mid Cap Value Momentum ETFVictory Capital Management Inc. | 45,839 | $4 M | 0.07% | 0.25% | new | Jun 30, 2026 |
| 🇺🇸 MFS New Discovery SeriesMASSACHUSETTS FINANCIAL SERVICES COMPANY | 44,125 | $4 M | 0.07% | 0.51% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC | 42,994 | $4 M | 0.06% | 0.07% | new | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 42,314 | $4 M | 0.06% | 0.03% | no change | Jul 31, 2026 |
| 🇺🇸 SMALLCAP World FundCapital Research and Management Company | 42,375 | $4 M | 0.06% | 0.16% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Advisor New Insights FundFidelity Management & Research Company LLC | 41,700 | $4 M | 0.06% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Balanced FundFidelity Management & Research Company LLC | 67,700 | $4 M | 0.10% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Multi-Manager Directional Alternative Strategies FundColumbia Management Investment Advisers, LLC | 40,805 | $4 M | 0.06% | 1.2% | +59% | Jul 31, 2026 |
| 🇸🇪 Handelsbanken Amerika Småbolag TemaHandelsbanken Fonder AB | 40,000 | $4 M | 0.06% | 0.41% | new | Jun 30, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 38,921 | $4 M | 0.06% | <0.01% | +11% | Jul 31, 2026 |
| 🇺🇸 Fidelity Contrafund K6Fidelity Management & Research Company LLC | 38,715 | $4 M | 0.06% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 35,495 | $3 M | 0.05% | 0.15% | +42% | Jun 30, 2026 |
| 🇸🇪 HealthInvest Sustainable HealthcareAtle Fund Management AB | 35,313 | $3 M | 0.05% | 0.90% | new | Jun 30, 2026 |
| 🇺🇸 Federated Hermes MDT Small Cap Growth FundFederated Hermes MDT Series | 33,226 | $3 M | 0.05% | 0.38% | new | Jul 31, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 32,257 | $3 M | 0.05% | <0.01% | +34% | Jul 31, 2026 |
| 🇺🇸 Victory Small Cap Stock FundVictory Capital Management Inc. | 32,066 | $3 M | 0.05% | 0.32% | new | Jul 31, 2026 |
| 🇺🇸 Capital Group U.S. Small and Mid Cap ETFCapital Research and Management Company | 52,068 | $3 M | 0.08% | 0.11% | new | May 31, 2026 |
| 🇺🇸 ALPS Medical Breakthroughs ETFALPS Advisors, Inc. | 49,896 | $3 M | 0.07% | 1.8% | +16% | May 31, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 29,860 | $3 M | 0.04% | 0.15% | +42% | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 29,232 | $3 M | 0.04% | <0.01% | +17% | Jun 30, 2026 |
| 🇺🇸 Optimum Small-Mid Cap Growth FundDelaware Management Company | 29,039 | $3 M | 0.04% | 0.29% | new | Jun 30, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 28,599 | $3 M | 0.04% | 0.04% | no change | Jul 31, 2026 |
| 🇺🇸 Janus Henderson Small Cap Growth Alpha ETFJanus Henderson Investors US LLC | 28,596 | $3 M | 0.04% | 0.76% | new | Jul 31, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences PortfolioT. Rowe Price Associates, Inc. | 28,926 | $3 M | 0.04% | 0.37% | no change | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Select FundNuveen Fund Advisors, LLC | 27,900 | $3 M | 0.04% | 0.66% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 27,467 | $3 M | 0.04% | <0.01% | +36% | Jul 31, 2026 |
| 🇺🇸 Fidelity Fundamental Small-Mid Cap ETFFidelity Management & Research Company LLC | 26,725 | $3 M | 0.04% | 0.17% | new | Jul 31, 2026 |
| 🇺🇸 Vanguard U.S. Momentum Factor ETFThe Vanguard Group, Inc. | 43,678 | $3 M | 0.06% | 0.14% | −31% | May 31, 2026 |
| 🇺🇸 Fidelity Blue Chip Growth K6 FundFidelity Management & Research Company LLC | 26,386 | $3 M | 0.04% | 0.01% | −0.8% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Oruka Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Joana GoncalvesChief Medical Officer | Option exercise10b5-1 plan | +3,500 | $6.840 | $24 K | 35,271 | Form 4 |
| filed | Joana GoncalvesChief Medical Officer | Option exercise10b5-1 plan | +3,500 | $7.800 | $27 K | 38,771 | Form 4 |
| filed | Joana GoncalvesChief Medical Officer | Sell10b5-1 plan | -2,600 | $99.52 | $259 K | 36,171 | Form 4 |
| filed | Joana GoncalvesChief Medical Officer | Sell10b5-1 plan | -1,500 | $100.48 | $151 K | 34,671 | Form 4 |
| filed | Joana GoncalvesChief Medical Officer | Sell10b5-1 plan | -1,900 | $101.53 | $193 K | 32,771 | Form 4 |
| filed | Joana GoncalvesChief Medical Officer | Sell10b5-1 plan | -300 | $102.47 | $31 K | 32,471 | Form 4 |
| filed | Joana GoncalvesChief Medical Officer | Sell10b5-1 plan | -200 | $103.36 | $21 K | 32,271 | Form 4 |
| filed | Joana GoncalvesChief Medical Officer | Sell10b5-1 plan | -500 | $105.86 | $53 K | 31,771 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Oruka Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-6.99 reverse split in the period to ; 1-for-5.99 reverse split in the period to
Fails to deliver
- : 4 shares at $95.81
- : 3,310 shares at $81.15
- : 15,722 shares at $79.92
- : 340 shares at $79.09
- : 62,016 shares at $83.29
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Oruka Therapeutics, Inc. scorecard#
Passes 1 of the 10 checks that could be worked out. Fiscal year 2025; market cap of Oct 28, 2026.
Valuation0 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median13.8×Price to book 13.8× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-1.4%Free cash flow is -1.4% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 1
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
- ✗Net income higher than five years earlier-$105 M-$105 M in fiscal 2025 against -$10 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$105 MNet income -$105 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-24.7%-24.7% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities22.4×Current ratio 22.37 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Oruka Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 | FY 2015to Dec 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | — | 0—— | 0—— | 0—— | 0—— | 0—— | 0—— | 0—— | 0—— | 0—— | |
| Research and development | 101—— | 1.0−78.7%— | 4.7−65.7%— | 14+177%— | 5.0+172%— | 1.8−56.8%— | 4.2−69.9%— | 14+14.0%— | 12+74.8%— | 7.1—— | |
| General and administrative | 21—— | 6.3+7.5%— | 5.8+6.3%— | 5.5+15.3%— | 4.8+19.9%— | 4.0+2.6%— | 3.9−16.3%— | 4.6+8.7%— | 4.3−2.9%— | 4.4—— | |
| Operating expenses | 122—— | 7.3−31.1%— | 11−45.2%— | 19+98.0%— | 9.8+68.0%— | 5.8−28.4%— | 8.1−56.6%— | 19+12.6%— | 17+45.0%— | 11—— | |
| Operating income | −122—— | −7.3—— | −11—— | −19—— | −9.8—— | −5.8—— | −8.1—— | −19—— | −17—— | −11—— | |
| Interest and finance income | 17—— | — | — | — | — | — | — | — | — | — | |
| Interest expense and finance costs | — | — | — | — | 0.0+28.6%— | 0.0−12.5%— | 0.0+33.3%— | 0.0—— | — | 0.0—— | |
| Other non-operating income (expense) | 17—— | — | — | — | — | — | — | — | — | — | |
| Income before tax | −105—— | — | — | −19—— | −9.7—— | −5.6—— | −8.0—— | −19—— | −16—— | — | |
| Income tax | — | 0—— | 0—— | 0—— | −0.0—— | −0.2—— | −0.0—— | −0.1—— | 0—— | 0—— | |
| Net income attributable to shareholders | −105—— | −5.3—— | −9.9—— | −19—— | −9.7—— | −5.5—— | −7.9—— | −18—— | −16—— | −11—— | |
| Earnings per share, basic | — | -0.37—— | -0.69—— | -1.39—— | -2.07—— | -4.15—— | -10.31r-0.57—— | -1.77—— | -1.81—— | -1.82—— | |
| Earnings per share, diluted | — | -0.37—— | -0.69—— | -1.39—— | -2.07—— | -4.15—— | -10.31r-0.57—— | -1.77—— | -1.81—— | -1.82—— | |
| Shares, weighted average (basic) | — | 14+0.0%— | 14+3.6%— | 14—— | — | — | — | — | — | — | |
| Shares, weighted average (diluted) | — | 14+0.0%— | 14+3.6%— | 14+195%— | 4.7+257%— | 1.3+71.7%— | 0.8r14−92.6%— | 10+15.0%— | 9.1+44.2%— | 6.3—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 47—9.6% | 37−11.8%98.9% | 42−20.5%98.5% | 53+8.7%97.2% | 49+487%97.3% | 8.4+26.6%98.0% | 6.6−24.1%96.8% | 8.7+17.6%70.4% | 7.4−80.9%30.0% | 39—98.0% | |
| Short-term investments | 290—59.4% | — | — | — | — | — | — | 3.1−77.8%24.7% | 14—55.9% | — | |
| Other current assets | 6.8—1.4% | 0.2−36.6%0.4% | 0.3−76.1%0.6% | 1.1+18.4%1.9% | 0.9+667%1.8% | 0.1−30.8%1.4% | 0.2−69.1%2.5% | 0.5+94.0%4.4% | 0.3+147%1.1% | 0.1—0.3% | |
| Current assets | 344—70.4% | 38−12.0%99.3% | 43−21.5%99.1% | 54+8.9%99.1% | 50+489%99.1% | 8.5+25.1%99.3% | 6.8−44.9%99.3% | 12−42.6%99.5% | 21−44.9%87.1% | 39—98.3% | |
| Property, plant and equipment | 0.3—0.1% | 0.0−60.0%0.0% | 0.0−47.9%0.1% | 0.0+129%0.1% | 0.0+110%0.0% | 0.0−58.3%0.1% | 0.0−42.9%0.4% | 0.0−36.4%0.3% | 0.1+136%0.3% | 0.0—0.1% | |
| Right-of-use (leased) assets | 1.8—0.4% | 0.2−28.0%0.7% | 0.3−21.5%0.8% | 0.4+2.1%0.8% | 0.4+1845%0.8% | 0.0—0.3% | — | — | — | — | |
| Total assets | 489—100% | 38−12.1%100% | 43−21.6%100% | 55+8.9%100% | 50+491%100% | 8.5+25.1%100% | 6.8−44.8%100% | 12−49.8%100% | 25−37.8%100% | 40—100% | |
| Accounts payable | 4.2—0.9% | 0.4+8.4%1.0% | 0.3−70.1%0.8% | 1.1−37.0%2.0% | 1.8+324%3.5% | 0.4+81.7%4.9% | 0.2−63.0%3.4% | 0.6−48.4%5.0% | 1.2+231%4.9% | 0.4—0.9% | |
| Current liabilities | 15—3.1% | 0.6−43.7%1.7% | 1.1−67.6%2.6% | 3.5−0.0%6.4% | 3.5+278%6.9% | 0.9+16.8%10.8% | 0.8−61.7%11.6% | 2.1−13.6%16.7% | 2.4+59.3%9.7% | 1.5—3.8% | |
| Lease liabilities (non-current) | 1.3—0.3% | 0.2−27.1%0.5% | 0.3−26.9%0.6% | 0.4−6.4%0.7% | 0.4—0.8% | — | — | — | — | — | |
| Total liabilities | 17—3.4% | 0.8−40.4%2.2% | 1.4−63.6%3.3% | 3.9−0.7%7.1% | 3.9+322%7.7% | 0.9+16.8%10.8% | 0.8−62.1%11.6% | 2.1−14.2%16.9% | 2.4+61.9%9.9% | 1.5—3.8% | |
| Retained earnings | −189—−38.7% | −189—−499% | −183—−426% | −173—−316% | −154—−306% | −144—−1692% | −139—−2036% | −131—−1059% | −113—−457% | −96—−243% | |
| Shareholders' equity | 472—96.6% | 37−11.2%97.8% | 42−18.4%96.7% | 51+9.7%92.9% | 47+511%92.3% | 7.6+26.2%89.2% | 6.0−41.3%88.4% | 10−53.7%83.1% | 22−41.7%90.1% | 38—96.2% | |
| Total liabilities and equity | 489—100% | 38−12.1%100% | 43−21.6%100% | 55+8.9%100% | 50+491%100% | 8.5+25.1%100% | 6.8−44.8%100% | 12−49.8%100% | 25−37.8%100% | 40—100% | |
| Shares outstanding | 49—— | 15+0.6%— | 140.0%— | 14+50.9%— | 9.5+499%— | 1.6+106%— | 0.8r14−93.4%— | 12+29.6%— | 9.1+0.3%— | 9.1—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | — | 0.0−25.0%— | 0.0+25.0%— | 0.0+100%— | 0.0−55.6%— | 0.0−18.2%— | 0.0−18.5%— | 0.0+12.5%— | 0.0+26.3%— | 0.0—— | |
| Share-based compensation | 24—— | 0.7+23.4%— | 0.6+11.9%— | 0.5+1056%— | 0.0−71.5%— | 0.2−44.7%— | 0.3−40.4%— | 0.5−20.5%— | 0.6−3.8%— | 0.6—— | |
| Cash from operating activities | −88—— | −5.0—— | −11—— | −19—— | −7.7—— | −4.8—— | −8.2—— | −17—— | −15—— | −11—— | |
| Capital expenditure | −0.2—— | 0—— | −0.0—— | −0.0—— | −0.0—— | −0.0—— | −0.0—— | −0.0—— | −0.0—— | −0.0—— | |
| Cash from investing activities | −97—— | 0—— | −0.0—— | −0.0—— | −0.0—— | −0.0−100%— | 3.0−76.4%— | 13—— | −16—— | −0.0—— | |
| Shares issued | 0.7—— | — | — | 24−52.7%— | 51+599%— | 7.3+106%— | 3.5−46.1%— | 6.6—— | — | 37—— | |
| Cash from financing activities | 170—— | 0—— | 0−100%— | 23−52.3%— | 48+639%— | 6.6+111%— | 3.1−46.9%— | 5.8—— | — | 34—— | |
| Change in cash | — | −5.0—— | −11−355%— | 4.3−89.5%— | 41+2220%— | 1.8—— | −2.1−261%— | 1.3—— | — | — | |
| Report | 10-Q | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 | Q2 FY2023to Jun 30, 2023 | Q1 FY2023to Mar 31, 2023 | Q4 FY2022to Dec 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | — | — | — | — | — | — | — | — | 0*—— | 0*—— | 0*—— | 0—— | 0*—— | |
| Research and development | 154—— | 54+85.2%— | 43+79.6%— | 29+46.3%— | 28*—— | 29—— | 24—— | 20—— | 0.0*−23.0%— | 0.3—— | 0.3—— | 0.4—— | 0.1*—— | |
| General and administrative | 29—— | 8.4+64.9%— | 6.9+57.8%— | 7.3+41.2%— | 6.8*—— | 5.1—— | 4.3—— | 5.2—— | 1.5*+3.8%— | 1.6—— | 1.7—— | 1.4—— | 1.5*—— | |
| Operating expenses | 183—— | 62+82.2%— | 50+76.3%— | 36+45.2%— | 34*—— | 34—— | 28—— | 25—— | 1.6*+2.7%— | 1.9—— | 2.0—— | 1.8—— | 1.5*—— | |
| Operating income | −183—— | −62—— | −50—— | −36—— | −34*—— | −34—— | −28—— | −25—— | −1.6*—— | −1.9—— | −2.0—— | −1.8—— | −1.5*—— | |
| Interest and finance income | 31—— | 12+217%— | 8.9+131%— | 4.6+12.6%— | 4.8*—— | 3.8—— | 3.9—— | 4.1—— | — | — | — | — | — | |
| Other non-operating income (expense) | 31—— | 12+218%— | 8.9+131%— | 4.6+12.9%— | 4.8*—— | 3.8—— | 3.9—— | 4.1—— | — | — | — | — | — | |
| Net income including minority interests | — | — | — | — | — | −30—— | −25—— | −21—— | — | — | — | — | — | |
| Net income attributable to shareholders | −153—— | −50—— | −41—— | −32—— | −30*—— | −30—— | −25—— | −21—— | −1.1—— | −1.4—— | −1.5—— | −1.3—— | −1.2—— | |
| Earnings per share, basic | — | — | — | — | — | — | -0.46—— | -0.40—— | — | -0.10—— | -0.10—— | -0.09—— | — | |
| Earnings per share, diluted | — | — | — | — | — | — | -0.46—— | -0.40—— | — | -0.10—— | -0.10—— | -0.09—— | — | |
| Shares, weighted average (basic) | — | — | — | — | — | — | 42—— | 42—— | — | 14—— | 14—— | 14—— | — | |
| Shares, weighted average (diluted) | — | — | — | — | — | — | 42—— | 42—— | — | 14—— | 14—— | 14—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 192—15.6% | 192+110%15.6% | 268+311%23.6% | 50−40.7%9.8% | 47—9.6% | 91—17.9% | 65—18.3% | 84—22.2% | 37−11.8%98.9% | 38—98.2% | 40—97.7% | 41—97.1% | 42—98.5% | |
| Short-term investments | 729—59.2% | 729+183%59.2% | 605+130%53.1% | 339+27.8%67.3% | 290—59.4% | 258—50.6% | 263—73.6% | 266—70.4% | — | — | — | — | — | |
| Other current assets | 21—1.7% | 21+253%1.7% | 11+205%1.0% | 6.4+115%1.3% | 6.8—1.4% | 6.0—1.2% | 3.6—1.0% | 3.0—0.8% | 0.2−36.6%0.4% | 0.4—1.0% | 0.6—1.5% | 0.9—2.0% | 0.3—0.6% | |
| Current assets | 941—76.5% | 941+165%76.5% | 885+166%77.6% | 395+12.3%78.3% | 344—70.4% | 355—69.7% | 332—92.9% | 352—93.4% | 38−12.0%99.3% | 39—99.3% | 41—99.2% | 42—99.2% | 43—99.1% | |
| Property, plant and equipment | 0.3—0.0% | 0.3+22.1%0.0% | 0.3+58.0%0.0% | 0.3+100%0.1% | 0.3—0.1% | 0.3—0.0% | 0.2—0.0% | 0.2—0.0% | 0.0−60.0%0.0% | 0.0—0.0% | 0.0—0.0% | 0.0—0.0% | 0.0—0.1% | |
| Right-of-use (leased) assets | 2.8—0.2% | 2.8+41.5%0.2% | 2.4+16.3%0.2% | 1.7+107%0.3% | 1.8—0.4% | 2.0—0.4% | 2.1—0.6% | 0.8—0.2% | 0.2−28.0%0.7% | 0.3—0.7% | 0.3—0.7% | 0.3—0.8% | 0.3—0.8% | |
| Total assets | 1,231—100% | 1,231+142%100% | 1,139+219%100% | 504+33.8%100% | 489—100% | 509—100% | 357—100% | 377—100% | 38−12.1%100% | 39—100% | 41—100% | 42—100% | 43—100% | |
| Accounts payable | 14—1.2% | 14+551%1.2% | 8.0+70.5%0.7% | 3.7+3.3%0.7% | 4.2—0.9% | 2.2—0.4% | 4.7—1.3% | 3.5—0.9% | 0.4+8.4%1.0% | 0.3—0.8% | 0.2—0.6% | 0.4—0.9% | 0.3—0.8% | |
| Current liabilities | 32—2.6% | 32+51.6%2.6% | 23+89.7%2.0% | 17+41.9%3.3% | 15—3.1% | 21—4.1% | 12—3.4% | 12—3.1% | 0.6−43.7%1.7% | 1.0—2.5% | 1.6—3.9% | 1.3—3.0% | 1.1—2.6% | |
| Lease liabilities (non-current) | 2.1—0.2% | 2.1+40.3%0.2% | 1.9+12.7%0.2% | 1.1+69.7%0.2% | 1.3—0.3% | 1.5—0.3% | 1.7—0.5% | 0.7—0.2% | 0.2−27.1%0.5% | 0.2—0.6% | 0.2—0.6% | 0.3—0.6% | 0.3—0.6% | |
| Total liabilities | 34—2.8% | 34+50.8%2.8% | 25+80.3%2.2% | 18+43.4%3.5% | 17—3.4% | 22—4.4% | 14—3.9% | 12—3.3% | 0.8−40.4%2.2% | 1.2—3.1% | 1.8—4.5% | 1.5—3.6% | 1.4—3.3% | |
| Retained earnings | −312—−25.4% | −312—−25.4% | −262—−23.0% | −221—−43.8% | −189—−38.7% | −160—−31.3% | −129—−36.2% | −105—−27.8% | −189—−499% | −188—−479% | −186—−453% | −185—−439% | −183—−426% | |
| Shareholders' equity | 1,197—97.2% | 1,197+146%97.2% | 1,115+224%97.8% | 487+33.4%96.5% | 472—96.6% | 487—95.6% | 344—96.1% | 365—96.7% | 37−11.2%97.8% | 38—96.9% | 39—95.5% | 41—96.4% | 42—96.7% | |
| Total liabilities and equity | 1,231—100% | 1,231+142%100% | 1,139+219%100% | 504+33.8%100% | 489—100% | 509—100% | 357—100% | 377—100% | 38−12.1%100% | 39—100% | 41—100% | 42—100% | 43—100% | |
| Shares outstanding | 67—— | 67+38.9%— | 61+63.1%— | 50+34.0%— | 49—— | 48—— | 37—— | 37—— | 15+0.6%— | 14—— | 14—— | 14—— | 14—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | — | — | 0.0*−40.0%— | 0.0*—— | 0.0*—— | 0.0—— | 0.0*—— | |
| Share-based compensation | 27—— | 9.1−10.2%— | 7.3+43.5%— | 7.0+42.7%— | 4.1*—— | 10—— | 5.1—— | 4.9—— | 0.1*+17.5%— | 0.2—— | 0.2—— | 0.2—— | 0.1*—— | |
| Cash from operating activities | −124—— | −44*—— | −33*—— | −24—— | −23*—— | −22*—— | −23*—— | −21—— | −1.1*—— | −1.7*—— | −0.7*—— | −1.6—— | −1.5*—— | |
| Capital expenditure | −0.2—— | −0.1*—— | 0*—— | −0.1—— | −0.1*—— | −0.1*—— | −0.0*—— | −0.0—— | — | — | — | — | 0*—— | |
| Cash from investing activities | −607—— | −159*—— | −411*−8556%— | −14−134%— | −22*—— | −122*—— | 4.9*—— | 43—— | — | — | 0*—— | 0—— | 0*—— | |
| Shares issued | 11—— | 4.3*—— | 4.4*—— | 1.7—— | 0.6*—— | 0*—— | — | — | — | — | — | — | — | |
| Cash from financing activities | 831—— | 127*−25.4%— | 663*—— | 41—— | 0.3*—— | 170*—— | — | — | — | — | 0*—— | 0—— | — | |
| Change in cash | — | — | — | — | — | — | — | — | −1.1*—— | −1.7*—— | −0.7*—— | −1.6—— | −1.5*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Where Oruka Therapeutics, Inc. operates: 1 country#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 1 subsidiaries on file.
Only the headquarters country is on file for Oruka Therapeutics, Inc.: no subsidiaries, branches, offices or country revenue elsewhere in the GLEIF register, its SEC filings or Wikidata.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters1 office1 subsidiary | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file; map outlines from Natural Earth. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at Oruka Therapeutics, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Chief executive | $3.4 M | $16.0 M | $2.3 M | $107 |
| 2024Chief executive | $854 K | $848 K | $462 K | $100 |
| 2023Chief executive | $359 K | $291 K | $362 K | $72 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Oruka Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Auditor changedFiling
Auditor changed 1 · Change in control 1 · Acquisition or sale completed 1 · Directors and officers 5 · Material agreement 7 · Unregistered share sale 2 · Shareholder rights changed 1 · Bylaws or fiscal year changed 2 · Shareholder vote 4 · Results announced 5
| Filed | What happened | Filing |
|---|---|---|
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Material agreementUnregistered share saleBylaws or fiscal year changed | 8-K | |
| Auditor changedChange in controlAcquisition or sale completedDirectors and officersMaterial agreementShareholder rights changedBylaws or fiscal year changedResults announced | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Aug 24, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2015 | $52 M | Private placement after listing | $50 to $250 million | 14 | equity, options | SEC |
| Jun 2013 | $1 M | Private placement after listing | Under $2 million | 2 | options | SEC |
| Jan 2013 | $1 M | Private placement after listing | Under $2 million | 5 | equity, options | SEC |
| Dec 2011 | $5 M | No. 1 | $2 to $10 million | 6 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2009 | · | · | · | · | 40 | · | · | · | · | · | · | · | 40 |
| 2008 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| 2007 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing | |
| 40 people | Restructuring planSEC 8-K | “(the “Company”) implemented a plan of restructuring under which it will terminate approximately 40 employees, effective May 20, 2009.” | Filing | |
| 37% of workforce | Restructuring planSEC 8-K | “(the “Company” or “Nuvelo”) adopted a plan of restructuring involving the termination of 20 research employees to reduce its current workforce by 37% percent.” | Filing | |
| 22% of workforce | Restructuring planSEC 8-K | “On March 17, 2008, Nuvelo announced that in connection with the discontinuation of its alfimeprase clinical development program, described below under Items 7.01 and 8.01, it was t…” | Filing | |
| 30% of workforce | Restructuring planSEC 8-K | “On August 1, 2007, Nuvelo announced that it was terminating employees to reduce its current workforce by approximately 30 percent and will suspend development of its product candid…” | Filing |
Source: State WARN notices and SEC 8-K item 2.05
Discuss Oruka Therapeutics, Inc.#
2 automatic updates and 0 member comments. Sign in to comment and react.
- Insider trading in October 2026automatic update · Oct 31, 2026
Directors and officers of Oruka Therapeutics, Inc. reported open-market trades for October 2026 (SEC Forms 4 and 5): 4 insiders sold shares worth about $4,126,865 in 17 trades. Awards, option exercises and shares withheld for tax are not counted.
- Mutual funds: 244 funds hold $2.1 billionautomatic update · Jul 31, 2026
244 mutual funds in 2 countries hold shares of Oruka Therapeutics, Inc. worth $2.1 billion, about 36.5% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 197 funds added shares and 32 sold; on balance they bought $971 million. Share splits are not counted as trading.
How Oruka Therapeutics, Inc. compares in Biotechnology
- Market cap$6.5 B · higher than 92% of 726
- Price / book13.8× · lower than 11% of 534
- FCF yield-1.4% · higher than 84% of 449
- 🇺🇸 CG Oncology, Inc.$6.6 B
- 🇺🇸 Belite Bio, Inc$6.4 B
- 🇺🇸 Immunovant, Inc.$6.6 B
- 🇮🇳 Biocon Limited$6.4 B
- 🇮🇪 Alkermes plc.$6.7 B
- 🇺🇸 Liquidia Technologies$6.1 B
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Oruka Therapeutics, Inc.🇺🇸 | $6.5 B | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- CG Oncology, Inc.$6.6 B
- Belite Bio, Inc$6.4 B
- Immunovant, Inc.$6.6 B
- Biocon Limited$6.4 B
- Alkermes plc.$6.7 B
- Liquidia Technologies$6.1 B
Sources and freshness
- Market cap:
- Oct 28, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Oruka Therapeutics, Inc.? Verify and update this profile — free
Show Oruka Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.